Slingshot members are tracking this event:

OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
OPK Community voting in process

Additional Information

Additional Relevant Details "This is a significant step in the development of another drug candidate utilizing our CTP technology," commented Phillip Frost, MD, Chairman and Chief Executive Officer of OPKO. "Later this year, we expect to initiate a second Phase 2a trial for Factor VIIa-CTP in a subcutaneous formulation that, if successful, could provide prophylactic therapy to prevent bleeding episodes and thereby change the treatment paradigm for patients with hemophilia."
Currently, Factor VIIa therapy is available only as an intravenous (IV) formulation which, due to Factor VIIa's short half-life, requires multiple infusions to treat a bleeding episode in hemophilia A or B patients with inhibitors. In addition, frequent infusions are onerous when used as prophylactic therapy, especially for children. Pre-clinical studies of intravenous and subcutaneous formulations of our product in hemophilic animal models demonstrated its duration of action and significantly increased survival.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2a, Clinical Study, Hemophilia, Hemophilia A, Hemophilia B